Navigation Links
Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
Date:9/14/2011

PITTSBURGH, Sept. 14, 2011 /PRNewswire/ -- Cohera Medical, Inc.®, a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.

TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical drains.  Its unique chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may provide the patient with a quicker return to normal activity.

"TissuGlu Surgical Adhesive provides an innovative approach to the way plastic surgeons address wound drainage challenges and helps plastic surgeons improve the overall care of their patients," said Dr. Peter Rubin, Chief, Division of Plastic and Reconstructive Surgery at the University of Pittsburgh Medical Center. "Surgeons will be eager to apply this product to their procedures, which we believe will ultimately save them time and money through the reduction of post-surgical complications and additional OR time."

TissuGlu will be commercially available in Germany in the third quarter of 2011.  Cohera Medical is also actively pursuing U.S. FDA approval.

"CE Mark approval moves Cohera from an early-stage company to a commercial entity," said Patrick Daly, President and Chief Executive Officer of Cohera Medical. "We look forward to beginning our commercialization in Germany, a strategic market, which we believe will demonstrate commercial viability for TissuGlu Surgical Adhesive and serve as a springboard for expansion across the EU and to other important markets, including the US."

According to the American Society of Plastic Surgeons, the global market for cosmetic surgery and treatments now exceeds $30 billion, with a sustainable compound annual growth rate in the range of 25%. In Europe, the market for cosmetic surgery is about $2.2 billion with a compound annual growth rate of 19% (Frost & Sullivan), and total sales of wound closure devices are expected to reach approximately $740 million in 2012 (Medtech Insight).  Abdominoplasty (tummy tucks) is the fourth most common plastic surgery procedure performed worldwide.

Currently, most patients who undergo abdominoplasty procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site.  In some cases, drainage is inadequate, and the excess fluid accumulation (seroma) often requires additional procedures for removal. TissuGlu adheres the tissue flap to the underlying tissue (which is created during the procedure) to reduce fluid that can accumulate in the space and ultimately reduce the time to drain removal.  With the use of TissuGlu, patients may have drains removed faster, which may lead to a more comfortable recovery and a quicker return to normal activity.

"Achieving the CE Mark on our TissuGlu Surgical Adhesive represents a significant milestone and achievement by all of the employees of Cohera Medical," said Chad A. Coberly, Vice President of Clinical, Regulatory and Legal Affairs for Cohera Medical. "The certification signifies that we have met the rigorous clinical, quality, and performance requirements of the EU authorities and demonstrates the commitment we have to our future customers, partners, and investors."

To view an animation of how TissuGlu Surgical Adhesive works, click here: http://www.coheramedical.com/products.

About Cohera Medical

Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is designed to reduce fluid accumulation and the need for surgical drains in patients undergoing abdominoplasty (tummy tuck) and other plastic surgery procedures that require the creation of large planar flaps of tissue. Cohera Medical is also developing surgical adhesives and sealants for use in bowel procedures, hernia mesh fixation and small bone fixation. Outside of the EU, TissuGlu Surgical Adhesive and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.

For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
2. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
3. Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011
4. Wanted: Fort Mill Medical Kit Assemblers
5. Medical Care Technologies Inc. Closes $200,000 Bridge Loan Financing for Kids Health Center
6. IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
7. First Client Installation of CyttaConnect™ Medical Monitoring System
8. Florida Medical Device Manufacturer Announces New Product Release for Radiation Therapy
9. CSA Medical Appoints Wendelin Maners VP of Emerging Therapies
10. Ventana Medical Systems, Inc. Unveils High-throughput Slide Scanner for Digital Pathology
11. MedInformatix Practice Management and Electronic Medical Records Simplifies Texas Dermatology Practices Current and Future Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena ... 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... online directory that recognizes local physicians and dentists who have earned high ratings and ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... 2017 , ... Healthcare Research & Analytics® (HRA®) in cooperation ... cancer, has produced a seminal study that asked cancer survivors and their caregivers ... a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates that ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
Breaking Medicine News(10 mins):